Become a Member
  • Track your favourite stocks
  • Create & monitor portfolios
  • Daily portfolio value
Sign Up
Quickpicks
Add shares to your
quickpicks to
display them here!

Int.biotech. (IBT) Share Price

Price 922.00p on 27-02-2026 at 19:40:06
Change 12.00p 1.32%
Buy 922.00p
Sell 912.00p
Last Trade: Buy 2,618.00 at 922.00p
Day's Volume: 34,042
Last Close: 922.00p
Open: 920.00p
ISIN: GB0004559349
Day's Range 912.00p - 922.00p
52wk Range: 480.00p - 1,000.00p
Market Capitalisation: £294.14m
VWAP: 921.42521p
Shares in Issue: 31.90m

Int.biotech. (IBT) Latest Trades

Buy/Sell Volume Trade Prc Trade Type Trade Time
Buy* 2,618 922.00p Suspected BUY Trade
16:35:00 - 27-Feb-26
Sell* 35 914.00p Automatic Execution
16:28:18 - 27-Feb-26
Sell* 3 910.00p SI Trade
16:23:34 - 27-Feb-26
Unknown* 0 920.00p SI Trade
16:20:44 - 27-Feb-26
Buy* 271 921.133p Suspected BUY Trade
16:17:58 - 27-Feb-26
Unknown* 0 924.00p SI Trade
16:10:39 - 27-Feb-26
Unknown* 0 928.00p SI Trade
15:58:25 - 27-Feb-26
Buy* 550 923.0951p Ordinary
15:55:14 - 27-Feb-26
Buy* 500 921.4935p Ordinary
15:53:47 - 27-Feb-26
Unknown* 0 922.00p SI Trade
15:27:54 - 27-Feb-26
See more Int.biotech. trades

Int.biotech. (IBT) Share Price History

Time period:
to
Date Open High Low Close Volume
27th Feb 2026 (Fri) 920.00 922.00 912.00 922.00 34,042
26th Feb 2026 (Thu) 928.00 928.00 910.00 910.00 17,920
25th Feb 2026 (Wed) 932.00 944.00 930.00 934.00 60,503
24th Feb 2026 (Tue) 932.00 936.00 924.00 934.00 38,913
23rd Feb 2026 (Mon) 918.00 932.00 918.00 922.00 54,236
20th Feb 2026 (Fri) 914.00 924.00 912.00 912.00 57,262
19th Feb 2026 (Thu) 914.00 914.00 900.00 906.00 22,998
18th Feb 2026 (Wed) 898.00 916.00 898.00 908.00 49,650
17th Feb 2026 (Tue) 888.00 900.00 888.00 890.00 38,102
16th Feb 2026 (Mon) 900.00 900.00 876.00 884.00 51,665
13th Feb 2026 (Fri) 888.00 898.00 888.00 892.00 75,077
12th Feb 2026 (Thu) 902.00 918.00 884.00 884.00 186,701
11th Feb 2026 (Wed) 904.00 920.00 894.00 896.00 56,033
10th Feb 2026 (Tue) 912.00 924.00 910.00 916.00 55,168
9th Feb 2026 (Mon) 910.00 914.00 900.00 912.00 53,195
6th Feb 2026 (Fri) 914.00 914.00 874.00 904.00 132,416
5th Feb 2026 (Thu) 930.00 936.00 918.00 918.00 47,121
4th Feb 2026 (Wed) 942.00 942.00 930.00 930.00 40,011
3rd Feb 2026 (Tue) 944.00 950.00 938.00 946.00 53,789
2nd Feb 2026 (Mon) 912.00 944.00 912.00 936.00 76,242
30th Jan 2026 (Fri) 930.00 930.00 914.00 918.00 83,252
29th Jan 2026 (Thu) 940.00 942.00 926.00 930.00 97,993
28th Jan 2026 (Wed) 952.00 956.00 940.00 940.00 70,909
See more Int.biotech. price history

Int.biotech. (IBT) Regulatory News

Date Source Headline
27th Feb 2026 11:14 am RNS Net Asset Value(s)
26th Feb 2026 11:49 am RNS Net Asset Value(s)
25th Feb 2026 11:54 am RNS Net Asset Value(s)
24th Feb 2026 11:43 am RNS Net Asset Value(s)
23rd Feb 2026 11:40 am RNS Net Asset Value(s)
20th Feb 2026 10:53 am RNS Net Asset Value(s)
19th Feb 2026 11:36 am RNS Net Asset Value(s)
18th Feb 2026 11:47 am RNS Net Asset Value(s)
17th Feb 2026 11:32 am RNS Net Asset Value(s)
16th Feb 2026 11:56 am RNS Net Asset Value(s)
See more Int.biotech. regulatory news

Int.biotech. (IBT) Share News

UK dividends calendar - next 7 days

16th Jan 2026 15:52

Read More

UK dividends calendar - next 7 days

22nd Dec 2025 14:43

Read More

International Biotechnology beats benchmark with 0.7% NAV gain

6th Nov 2025 19:17

(Alliance News) - International Biotechnology Trust PLC on Thursday said its portfolio continued to outperform the sector benchmark as the company reported full-year results. Read More

IN BRIEF: International Biotechnology Trust notes Novo to buy Akero

9th Oct 2025 15:40

International Biotechnology Trust PLC - investor in biotech and life science companies - Notes portfolio firm Akero Therapeutics Inc as agreed to be taken over by Novo Nordisk AS in a deal worth up to EUR5.2 billion. Novo Nordisk will pay an initial USD54 per share, with a contingent portion of the deal worth USD6 per share. The Bagsvaerd, Denmark-based pharmaceuticals company will pay an initial EUR4.7 billion to buy the firm, and a potential additional payment of EUR500 million, hinging on US regulatory approval for key Akero treatment Efruxifermin. The deal adds Akero's Efruxifermin to Novo Nordisk's portfolio. The asset is aimed at treating metabolic dysfunction-associated steatohepatitis, a disease caused by fat buildup in the liver. Read More

International Biotechnology to raise unquoted exposure with Schroders

2nd Oct 2025 13:31

(Alliance News) - International Biotechnology Trust PLC on Thursday said it has partnered with Schroders Capital to access more investees in the earlier stages of development. Read More

See more Int.biotech. news
FTSE 100 Latest
Value10,910.55
Change63.85

Login to your account

Forgot Password?

Not Registered